UA107560C2 - Фармацевтична лікарська форма для негайного вивільнення похідної індолінону - Google Patents

Фармацевтична лікарська форма для негайного вивільнення похідної індолінону

Info

Publication number: UA107560C2
Authority: UA; Ukraine
Prior art keywords: indolinon; derivatives; immediate release; pharmaceutical form; active substance
Prior art date: 2008-06-06

Application number

UAA201100096A

Other languages

English (en)

Russian (ru)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-06

Filing date

2009-04-06

Publication date

2015-01-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41017080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA107560(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-04-06 Application filed filed Critical

2015-01-26 Publication of UA107560C2 publication Critical patent/UA107560C2/ru

Links

239000012729 immediate-release (IR) formulation Substances 0.000 title 1
JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
239000013543 active substance Substances 0.000 abstract 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
229940067606 lecithin Drugs 0.000 abstract 1
235000010445 lecithin Nutrition 0.000 abstract 1
239000000787 lecithin Substances 0.000 abstract 1
150000002632 lipids Chemical class 0.000 abstract 1
229940057917 medium chain triglycerides Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
MMMVNAGRWOJNMW-FJBFXRHMSA-N nintedanib esylate Chemical compound CCS(O)(=O)=O.O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 MMMVNAGRWOJNMW-FJBFXRHMSA-N 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
239000000725 suspension Substances 0.000 abstract 1
239000007966 viscous suspension Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Business, Economics & Management (AREA)
Physics & Mathematics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Pathology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Medical Informatics (AREA)
Neurology (AREA)
Surgery (AREA)
Dispersion Chemistry (AREA)
Entrepreneurship & Innovation (AREA)
Educational Administration (AREA)
Educational Technology (AREA)
General Physics & Mathematics (AREA)
Theoretical Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

UAA201100096A 2008-06-06 2009-04-06 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону UA107560C2 (uk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08157750		2008-06-06
PCT/EP2009/056895 WO2009147220A1 (fr)	2008-06-06	2009-06-04	Forme posologique pharmaceutique pour libération immédiate de dérivé d'indolinone

Publications (1)

Publication Number	Publication Date
UA107560C2 true UA107560C2 (uk)	2015-01-26

Family

ID=41017080

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA201100096A UA107560C2 (uk)	2008-06-06	2009-04-06	Фармацевтична лікарська форма для негайного вивільнення похідної індолінону

Country Status (35)

Country	Link
US (3)	US20110190318A1 (fr)
EP (1)	EP2313087B2 (fr)
JP (2)	JP5583119B2 (fr)
KR (1)	KR20110022586A (fr)
CN (1)	CN102056599A (fr)
AR (1)	AR072060A1 (fr)
AU (1)	AU2009254556B2 (fr)
BR (1)	BRPI0913235A2 (fr)
CA (1)	CA2726648A1 (fr)
CL (1)	CL2010001362A1 (fr)
CO (1)	CO6280468A2 (fr)
CY (1)	CY1121272T1 (fr)
DK (1)	DK2313087T4 (fr)
EA (1)	EA201001857A1 (fr)
EC (1)	ECSP10010717A (fr)
ES (1)	ES2711913T5 (fr)
FI (1)	FI2313087T4 (fr)
HR (1)	HRP20190181T4 (fr)
HU (1)	HUE042524T2 (fr)
IL (1)	IL209055A0 (fr)
LT (1)	LT2313087T (fr)
MA (1)	MA32386B1 (fr)
MX (1)	MX338001B (fr)
PE (1)	PE20100050A1 (fr)
PL (1)	PL2313087T5 (fr)
PT (1)	PT2313087T (fr)
RS (1)	RS58280B2 (fr)
SG (1)	SG191607A1 (fr)
SI (1)	SI2313087T2 (fr)
TR (1)	TR201901579T4 (fr)
TW (1)	TW201002692A (fr)
UA (1)	UA107560C2 (fr)
UY (1)	UY31876A (fr)
WO (1)	WO2009147220A1 (fr)
ZA (1)	ZA201007972B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040077604A1 (en)	2001-12-19	2004-04-22	Lenard Lichtenberger	Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
UA104590C2 (ru) *	2008-06-06	2014-02-25	Берингер Ингельхайм Интернациональ Гмбх	Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона
JP2015532272A (ja)	2012-09-28	2015-11-09	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
US20140350022A1 (en)	2013-05-10	2014-11-27	Boehringer Ingelheim International Gmbh	Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN105377965B (zh)	2013-06-04	2019-05-10	蒙诺苏尔有限公司	水溶性膜密封溶液、相关方法和相关物品
EP3782604A1 (fr)	2013-07-31	2021-02-24	Windward Pharma, Inc.	Composés inhibiteurs de tyrosine kinase en aérosol et leurs utilisations
KR20260025887A (ko)	2015-06-06	2026-02-24	클라우드브레이크 테라퓨틱스, 엘엘씨	익상편을 치료하기 위한 조성물 및 방법
AU2017274195B2 (en)	2016-06-02	2022-04-07	Ads Therapeutics Llc	Compositions and methods of using nintedanib for improving glaucoma surgery success
JP2019536812A (ja)	2016-12-12	2019-12-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
CN110573161A (zh) *	2017-03-28	2019-12-13	勃林格殷格翰国际有限公司	用于治疗肌营养不良的方法的尼达尼布
IL273169B2 (en)	2017-10-23	2024-05-01	Boehringer Ingelheim Int	New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
FI3761980T3 (fi)	2018-03-07	2024-02-21	Pliant Therapeutics Inc	Aminohappoyhdisteitä ja käyttömenetelmiä
US20230135671A1 (en)	2020-04-01	2023-05-04	Boehringer Ingelheim International Gmbh	Use of biomarkers in the treatment of fibrotic conditions
EP4098246A1 (fr)	2021-05-31	2022-12-07	Lotus Pharmaceutical Co., Ltd.	Formulation de nintedanib
CN119630398A (zh)	2022-08-16	2025-03-14	勃林格殷格翰国际有限公司	眼内用尼达尼布的药物制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3579384D1 (de)	1984-07-24	1990-10-04	Scherer Gmbh R P	Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung.
DE19603402A1 (de)	1995-02-24	1996-08-29	Basf Ag	Weichgelatinekapseln
US6762180B1 (en)	1999-10-13	2004-07-13	Boehringer Ingelheim Pharma Kg	Substituted indolines which inhibit receptor tyrosine kinases
DE10233500A1 (de)	2002-07-24	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) *	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
PE20060777A1 (es) *	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PT1948180E (pt) *	2005-11-11	2013-05-10	Boehringer Ingelheim Int	Tratamento de combinação de cancro compreendendo inibidores de egfr/her2
ME02273B (me) *	2008-06-06	2016-02-20	Boehringer Ingelheim Int	Farmaceutska kombinacija
UA104590C2 (ru) *	2008-06-06	2014-02-25	Берингер Ингельхайм Интернациональ Гмбх	Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона
US20120157472A1 (en) *	2009-01-14	2012-06-21	Boehringer Ingelheim International Gmbh	Method for treating colorectal cancer
US8802384B2 (en) *	2009-03-12	2014-08-12	Boehringer Ingelheim International Gmbh	Method or system using biomarkers for the monitoring of a treatment
US20120142703A1 (en) *	2009-05-14	2012-06-07	Boehringer Ingelheim International Gmbh	New combination therapy in treatment of oncological and fibrotic diseases

2009
- 2009-04-06 UA UAA201100096A patent/UA107560C2/ru unknown
- 2009-06-04 HU HUE09757601A patent/HUE042524T2/hu unknown
- 2009-06-04 KR KR1020107027313A patent/KR20110022586A/ko not_active Ceased
- 2009-06-04 AU AU2009254556A patent/AU2009254556B2/en active Active
- 2009-06-04 JP JP2011512134A patent/JP5583119B2/ja active Active
- 2009-06-04 SI SI200931930T patent/SI2313087T2/sl unknown
- 2009-06-04 PL PL09757601.1T patent/PL2313087T5/pl unknown
- 2009-06-04 US US12/995,893 patent/US20110190318A1/en not_active Abandoned
- 2009-06-04 EA EA201001857A patent/EA201001857A1/ru unknown
- 2009-06-04 WO PCT/EP2009/056895 patent/WO2009147220A1/fr not_active Ceased
- 2009-06-04 LT LTEP09757601.1T patent/LT2313087T/lt unknown
- 2009-06-04 RS RS20190128A patent/RS58280B2/sr unknown
- 2009-06-04 TR TR2019/01579T patent/TR201901579T4/tr unknown
- 2009-06-04 CN CN200980121070XA patent/CN102056599A/zh active Pending
- 2009-06-04 PT PT09757601T patent/PT2313087T/pt unknown
- 2009-06-04 BR BRPI0913235A patent/BRPI0913235A2/pt not_active IP Right Cessation
- 2009-06-04 FI FIEP09757601.1T patent/FI2313087T4/fi active
- 2009-06-04 ES ES09757601T patent/ES2711913T5/es active Active
- 2009-06-04 CA CA2726648A patent/CA2726648A1/fr not_active Abandoned
- 2009-06-04 EP EP09757601.1A patent/EP2313087B2/fr active Active
- 2009-06-04 MX MX2010013092A patent/MX338001B/es active IP Right Grant
- 2009-06-04 PE PE2009000780A patent/PE20100050A1/es not_active Application Discontinuation
- 2009-06-04 SG SG2013040332A patent/SG191607A1/en unknown
- 2009-06-04 DK DK09757601.1T patent/DK2313087T4/da active
- 2009-06-04 HR HRP20190181TT patent/HRP20190181T4/hr unknown
- 2009-06-05 AR ARP090102040A patent/AR072060A1/es unknown
- 2009-06-05 TW TW098118827A patent/TW201002692A/zh unknown
- 2009-06-08 UY UY0001031876A patent/UY31876A/es not_active Application Discontinuation
2010
- 2010-11-01 IL IL209055A patent/IL209055A0/en unknown
- 2010-11-08 ZA ZA2010/07972A patent/ZA201007972B/en unknown
- 2010-12-03 CO CO10152530A patent/CO6280468A2/es not_active Application Discontinuation
- 2010-12-06 CL CL2010001362A patent/CL2010001362A1/es unknown
- 2010-12-06 MA MA33403A patent/MA32386B1/fr unknown
- 2010-12-23 EC EC2010010717A patent/ECSP10010717A/es unknown
2013
- 2013-03-08 US US13/790,334 patent/US20130203773A1/en not_active Abandoned
2014
- 2014-02-10 US US14/176,478 patent/US20140163040A1/en not_active Abandoned
- 2014-02-28 JP JP2014039871A patent/JP5992937B2/ja active Active
2019
- 2019-02-19 CY CY20191100212T patent/CY1121272T1/el unknown

Also Published As

Publication number	Publication date
ZA201007972B (en)	2011-07-27
IL209055A0 (en)	2011-01-31
DK2313087T3 (en)	2019-02-18
MA32386B1 (fr)	2011-06-01
HRP20190181T1 (hr)	2019-03-22
MX338001B (es)	2016-03-30
PL2313087T3 (pl)	2019-05-31
JP5992937B2 (ja)	2016-09-14
ES2711913T3 (es)	2019-05-08
EP2313087B2 (fr)	2023-11-22
SG191607A1 (en)	2013-07-31
KR20110022586A (ko)	2011-03-07
HRP20190181T4 (hr)	2024-07-05
SI2313087T1 (sl)	2019-03-29
CL2010001362A1 (es)	2011-05-13
RS58280B2 (sr)	2024-02-29
MX2010013092A (es)	2011-02-25
US20130203773A1 (en)	2013-08-08
PL2313087T5 (pl)	2024-03-04
SI2313087T2 (sl)	2024-03-29
WO2009147220A1 (fr)	2009-12-10
PT2313087T (pt)	2019-02-15
AR072060A1 (es)	2010-08-04
JP2011522010A (ja)	2011-07-28
US20140163040A1 (en)	2014-06-12
EP2313087B1 (fr)	2018-11-21
TR201901579T4 (tr)	2019-02-21
FI2313087T4 (fi)	2023-12-28
DK2313087T4 (da)	2024-01-15
EP2313087A1 (fr)	2011-04-27
CA2726648A1 (fr)	2009-12-10
CY1121272T1 (el)	2020-05-29
CO6280468A2 (es)	2011-05-20
ES2711913T5 (es)	2024-06-24
UY31876A (es)	2010-01-29
JP5583119B2 (ja)	2014-09-03
TW201002692A (en)	2010-01-16
HUE042524T2 (hu)	2019-07-29
ECSP10010717A (es)	2011-02-28
JP2014098045A (ja)	2014-05-29
PE20100050A1 (es)	2010-01-29
RS58280B1 (sr)	2019-03-29
AU2009254556B2 (en)	2015-08-20
LT2313087T (lt)	2019-02-25
CN102056599A (zh)	2011-05-11
AU2009254556A1 (en)	2009-12-10
BRPI0913235A2 (pt)	2016-01-19
EA201001857A1 (ru)	2011-06-30
US20110190318A1 (en)	2011-08-04

Publication	Publication Date	Title
UA107560C2 (uk)	2015-01-26	Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
UY30477A1 (es)	2009-04-30	Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
SV2008001369A (es)	2008-03-26	Benzimidazoles
CO6351726A2 (es)	2011-12-20	Compuestos pirazolicos 436
CL2010001279A1 (es)	2011-05-13	Forma de dosificacion que comprende 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona-monoetanosulfonato, un vehiculo lipidico, un espesante y un agente de deslizamiento/solubilizante, de grupos definidos.
CY1109010T1 (el)	2014-07-02	γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
PY0723043A (es)	2012-11-01	Derivados de N-(Amino-heteroaril)-1H-Indol-2-carboxamidas, su preparación y su aplicación en terapéutica.
NO20081878L (no)	2008-04-18	Diacylindazolderivater som lipase- og fosfolipaseinhibitorer
EA200700118A1 (ru)	2007-08-31	Амидосоединения и их применение в качестве лекарственных средств
CY1114925T1 (el)	2015-12-09	Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
MA31874B1 (fr)	2010-11-01	Inhibiteurs de bêta-lactamases
EA201070698A1 (ru)	2011-02-28	Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
CY1111197T1 (el)	2015-06-11	Tριαζολες χρησιμες ως αναστολεις πρετεϊνικων κινασων
CY1115188T1 (el)	2017-01-04	Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axl
EP2066350A4 (fr)	2010-04-07	Formulations stabilisees d'anticorps et leurs utilisations
EP2131848A4 (fr)	2012-06-27	Compositions et methodes de potentialisation de l'activite de molecules biologiquement actives
CY1111070T1 (el)	2015-06-11	Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
EP2130552A4 (fr)	2011-03-02	Composition pharmaceutique comportant un anticorps anti-grp 78 en tant qu'ingredient actif
MA32150B1 (fr)	2011-03-01	Inhibiteurs heterocycliques de la stearoyl-coa desaturase
NO20080220L (no)	2008-04-21	Formuleringer med hoy medikament belastning og doseringsformer
MA32776B1 (fr)	2011-11-01	Inhibiteurs de l'akt et de la p70 s6 kinase
EP2348018A4 (fr)	2012-04-25	Dérivé biarylique hétérocyclique et inhibiteur de pde le renfermant en tant qu'ingrédient actif
CY1110213T1 (el)	2012-05-23	Παραγωγα αζολοπυριδιν-2-ονης ως αναστολεις λιπασων και φωσφολιπασων
UY29872A1 (es)	2007-05-31	Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas
WO2006136580A3 (fr)	2007-04-12	Nouveaux derives de 2-(phenylamino)benzimidazole et utilisation de ceux-ci en tant que modulateurs de canaux de potassium actives par le calcium a faible conductance